

**THOMAS IRA MARGOLIS, M. D.**

**OFFICE ADDRESS:**

1500 Tilton Road  
Northfield, NJ 08225  
Phone: 609-646-5200  
Fax: 609-646-9868

**BIRTH DATE:** May 11, 1962

**PLACE OF BIRTH:** Uniontown, PA

**PROFESSIONAL EXPERIENCE**

RETINAL AND OPHTHALMIC CONSULTANTS, PC, Northfield, NJ, 1995 - Present. Private group practice limited to vitreoretinal diseases and surgery. Participation in clinical trials.

**EDUCATION**

HARVARD MEDICAL SCHOOL, Boston, MA, 1984-1989. MD, Magna Cum Laude. Honors thesis: "New Mid-Infrared Lasers for Vitreous Membrane Cutting and Sclerostomy".

UNIVERSITY OF PENNSYLVANIA, Philadelphia, PA, 1980-84. BA in Economics and Chemistry (with honors). Summa Cum Laude.

UNIONTOWN AREA SENIOR HIGH SCHOOL, Uniontown, PA. Valedictorian, 1980.

**POSTGRADUATE TRAINING**

NEW ENGLAND EYE CENTER, TUFTS UNIVERSITY SCHOOL OF MEDICINE, Boston, MA, 1993-1995. Vitreoretinal fellowship.

WILLS EYE HOSPITAL, THOMAS JEFFERSON UNIVERSITY SCHOOL OF MEDICINE, Philadelphia, PA, 1990-1993. Ophthalmology residency.

CEDARS-SINAI MEDICAL CENTER, UCLA SCHOOL OF MEDICINE, Los Angeles, CA, 1989-90. Internal medicine internship.

MASSACHUSETTS EYE AND EAR INFIRMARY, HARVARD MEDICAL SCHOOL, Boston, MA. Laser research fellowship. 1987-1988.

**ACADEMIC APPOINTMENT**

TUFTS UNIVERSITY SCHOOL OF MEDICINE: Instructor-in-Ophthalmology, 1993-1995.

## **HOSPITAL APPOINTMENTS**

SHORE MEDICAL CENTER (SHORE MEMORIAL HOSPITAL), Somers Point, NJ:  
Attending Ophthalmologist, 1995-present.

ATLANTICARE REGIONAL MEDICAL CENTER, Atlantic City, NJ: Attending  
Ophthalmologist, 1995-present.

BETTY BACHARACH REHABILITATION HOSPITAL, Pomona, NJ: Consulting  
Ophthalmologist, 1995-2010.

NEW ENGLAND MEDICAL CENTER, Boston, MA: Assistant-in-Ophthalmology, 1993-1995.

MASSACHUSETTS EYE AND EAR INFIRMARY, Boston, MA: Assistant-in-Ophthalmology,  
1994-1995.

BOSTON VETERANS ADMINISTRATION MEDICAL CENTER, Boston, MA: Attending  
Ophthalmologist, 1993-1995.

## **CERTIFICATION AND LICENSURE**

New Jersey 1991-present

Pennsylvania 1991-present

Massachusetts Inactive

American Board of Ophthalmology, Diplomate 1995; Recertified 2005, 2015

National Board of Medical Examiners, Diplomate 1990

Certified examiner for STOP-ROP Study (Supplemental Therapeutic Oxygen for  
Pre-Threshold Retinopathy of Prematurity) 1993-1995

## **AWARDS AND HONORS**

*Philadelphia* magazine's Top Docs™ 2004 - 2019

*Inside Jersey* Top Doctors 2010 – 2017

NJ Top Docs 2018

Marquis Who's Who in the World®, 2015-2016

Marquis Who's Who in America, 2004-2016

Marquis Who's Who in the East, 2015-2016

Marquis Who's Who in Science and Engineering, 2016-2017

*Suburban Life* Top Doctors 2016

*US News and World Report*, "Top Doctors" 2012 and 2013

*New Jersey Monthly*, "The Best Doctors in New Jersey" September, 2003 and September, 2005

*New Jersey Life Magazine*, "Top Docs" March, 2005

"America's Top Ophthalmologists", Consumer's Research Council of America, 2004 - 2014

Strathmore's Who's Who, 2005-2006  
National Register's WHO'S WHO IN EXECUTIVES & PROFESSIONALS, 2004 - 2006  
Laurence B. Ellis Scholar-Harvard Medical School-1987-88  
Soma Weiss Assembly-Harvard Medical School-1986, 1989  
Merck Senior Chemistry Award-University of Pennsylvania-1984  
Phi Beta Kappa-1983  
Benjamin Franklin Scholar-University of Pennsylvania-1980-84  
Alpha Epsilon Delta Pre-Medical Honor Society-1983

### **MAJOR MEMBERSHIPS/COMMITTEES**

Atlantic County Medical Society 1995 – present  
    President 2007-8; Executive Committee, 2003 - present  
Medical Society of New Jersey, Credentials Committee, 2001 - present  
New Jersey Medical Board, Expert Reviewer, 1995 - present  
American Society of Retina Specialists 1996 - present  
Retina Society of New Jersey 1995 - present  
New Jersey Academy of Ophthalmology 1995 - present  
Medical Society of New Jersey 1995 - present  
Wills Eye Hospital Society 1993 - present  
American Academy of Ophthalmology 1990 - present  
American Medical Association 1989 - present  
Association for Research in Vision and Ophthalmology 1988 - 2002  
University of Pennsylvania Career Network Advisor 1995 – present

### **RESEARCH EXPERIENCE**

#### **Yosemite GR40349 – Principal Investigator**

F. Hoffmann-La Roche Ltd  
July 2018 – Present

Phase III, Multicenter, Randomized, Double-Masked, Active Comparator–Controlled Study to Evaluate the Efficacy and Safety of RO6867461 in Patients with Diabetic Macular Edema.

#### **Aerpio AKB-9778-CI-5001 – Sub-Investigator**

Aerpio Therapeutics LLC  
August 2017 – May 2018

Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15MG Once Daily or 15MG Twice Daily for 12 Months in Patients with Moderate to Severe Non-Proliferative Diabetic Retinopathy.

**Omaspect Extension Study of Spectri GX30191 – Sub-Investigator**

F. Hoffman-La Roche Ltd  
March 2017 – April 2018

A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study.

**TOGA-01 Phase II/III – Sub-Investigator**

University of Virginia Department of Ophthalmology  
February 2017 – Present

A Randomized, Double Masked, Placebo-Controlled Study Evaluating ORACEA® in Subjects with Geographic Atrophy Secondary to Non-Exudative Age-Related Macular Degeneration

**MAKO-OHR-1601 / Chiltern Study Code No. 35544 – Sub-Investigator**

OHR Pharmaceutical, Inc.  
June 2016 – July 2017

Phase III Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution, 0.2% Twice Daily in Subjects with Neovascular Age-Related Macular Degeneration.

**Protocol W – Sub-Investigator**

DRCR.net  
May 2016 – July 2018

Intravitreal Anti-VEGF Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk

**Capella R2176-3-AMD-1417 – Principal Investigator**

Regeneron  
September 2015 – September 2016

A Phase 2, Double-Masked, Randomized, Controlled, Multiple-Dose, Regimen-Ranging Study of the Efficacy and Safety of Intravitreal REGN2176-3 in Patients with Neovascular Age-Related Macular Degeneration.

**Spectri GX29185 – Sub-Investigator**

F. Hoffman-La Roche Ltd  
August 2014 – April 2018

A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration.

**SCORE2 – Principal Investigator**

National Eye Institute, National Institutes of Health, Department of Health and Human Services  
March 2014 - 2015

Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2): A Multicenter, Prospective, Randomized, Phase III Non-Inferiority Trial of Eyes with Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks Versus Intravitreal Aflibercept Every 4 Weeks.

**ORBIT TG-MV-018 – Principal Investigator**

ThromboGenics, Inc.  
February 2014 - 2015

A Multicenter, Prospective, Observational Phase 4 Study That Will Assess Clinical Outcomes and Safety of Jetrea Administered in a Real-World Setting for the Treatment of Symptomatic Vitreomacular Adhesion (VMA) by Assessing Anatomical and Functional Outcomes in 1500 Patients Recruited Across Approximately 120 USA Retina Sites.

**Eclipse OPH1002A – Sub-Investigator**

Ophthotech Corp  
September 2013 – August 2016

A Phase III Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreal Administration of Fovista (Anti PDGF-B Pegylated Aptamer) Administered in Combination with Lucentis Compared to Lucentis Monotherapy in Subjects with Subfoveal Neovascular Age-Related Macular Degeneration.

**BAM 114341 – Sub-Investigator**

Glaxo Smith Kline  
March 2013 - 2015

A phase II Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of GSK933776 in Adult Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD).

**VGFTe-AMD-1124 – Principal Investigator**

Regeneron  
January 2013 - 2014

An Open-Label Study of the Efficacy, Safety and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection) in Patients with Neovascular Age-Related Macular Degeneration.

**Protocol S – Sub-Investigator**

DRCR.net

July 2012 – April 2018

Prompt Panretinal Photocoagulation versus Ranibizumab and Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy Studies.

**Protocol V – Sub-Investigator**

DRCR.net

July 2012 – July 2018

Treatment for Central-Involved Diabetic Macular Edema in Eyes with Very Good Visual Acuity

**VIBRANT – Principal Investigator**

Regeneron

June 2012 - 2013

Protocol: VGFT e-RVO-1027

A Double-Masked, Randomized, Active-Controlled Study of the Efficacy, Safety and Tolerability of Intravitreal Administration of VEGF Trap-Eye (intravitreal aflibercept injection(IAI) in patients with macular edema secondary to branch retinal vein occlusion).

**SAKURA – Sub-Investigator**

Santen Incorporated

2011 - 2013

Protocol No. 32-007P

Phase III, Multinational, Multi-Center, Randomized, Double-Masked Study Assessing the Safety and Efficacy of Intravitreal Injections of DE-109 (three doses) for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye

**VISTA – Principal Investigator**

Regeneron

2011 - 2013

Protocol: VGFT-OD-1009

A Double-Masked, Randomized, Active-Controlled, Phase3. A Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trap-Eye in Patients with Diabetic Macular Edema.  
PAREXEL # 201601

**SHORE – Sub-Investigator**

Genentech  
2011 - 2013  
BB-IND 8633 – Protocol FVF4967g

A Multi-center Randomized Study Evaluating Dosing Regimens For Treatment with Intravitreal Ranibizumab Injections in Subjects with Macular Edema Following Retinal Vein Occlusion.

**VIEW 1 Extension – Principal Investigator**

Regeneron  
2010 - 2012  
Protocol: VGFT-OD-0910

Open-Label, Long-Term, Safety and Tolerability Extension Study of Intravitreal VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration.

**NAION – Sub-Investigator**

Covance  
2009 – April 2018  
Protocol: 12912

Prospective Case Crossover Study to Assess Whether PDE5 Inhibitor Exposure in Men with Erectile Dysfunction Increases the Risk for the Development of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION).

**COPERNICUS – Principal-Investigator**

Regeneron  
2009 - April 2012  
Protocol: VGFT-OD-0819

Randomized, Double-Masked, Controlled Phase III Study of the Efficacy, Safety and Tolerability of Repeated Administration of VEGF Trap-Eye in Subjects with Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO).

**HARBOR – Sub-Investigator**

Genentech  
2009 - 2012  
Protocol: FVF4579G

Phase III, Double-Masked, Multi-Center, Randomized, Active Treatment, Controlled Study of the Efficacy and Safety of 0.5 mg and 2.0 mg Ranibizumab; Administered Monthly or on an As-Needed Basis (PRN) in Patients with Subfoveal Neovascular Age-Related Macular Degeneration.

**RISE – Sub-Investigator**

Genentech  
2008 - 2012  
Protocol: FVF4170G

Three-Year Multi-Center Study with Monthly Visits for Patients with Diabetic Macular Edema Comparing Lucentis with Standard of Care Laser Treatments.

**CRUISE – Sub-Investigator**

Genentech  
2008 - 2010  
Protocol: FVF41669

One Year Multi-Center Study with Monthly Visits Comparing Lucentis to Sham Procedure for Patients with Central Retinal Vein Occlusion.

**DAVINCI – Principal Investigator**

Regeneron  
2008 - 2010  
Protocol: VGFT-OD-0706

A Double-Masked, Randomized, Controlled Study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administration of VEGF Trap-Eye in Patients with Diabetic Macular Edema (DME).

**HORIZON – Sub-Investigator**

Genentech  
2008 - 2010  
Protocol: FVF3426G

Open-Label, Multi-Center Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects with Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) or Macular Edema Secondary to Retinal Vein Occlusion (RVO) who have Completed a Genentech-Sponsored Ranizumab Study.

**VIEW1 – Principal Investigator**

Regeneron  
2007 - 2010  
Protocol: VGFT-OD-0605

Two Year Multi-Center Study with Monthly Visits Comparing VEGF-Trap Against Lucentis for Patients with Newly-Diagnosed, Age-Related Macular Degeneration.



**SIRIUS – Principal Investigator**

Allergan  
2006 - 2008  
Protocol: 211745-001-01

Two Year Multi-Center Study Comparing Sirna Against Lucentis for Age-Related Macular Degeneration

**NOTAL VISION HMP-V4 – Sub-Investigator**

Notal Vision  
2006 - 2007  
Protocol: 20071801

Sensitivity of the Home Macular Perimeter (HMP) in Detection of Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (ARMD)

**SAILOR – Sub-Investigator**

Genentech, Inc.  
2003 - 2007  
Protocol: FVF3689G

One Year Multi-Center Study to Evaluate the Safety and Tolerability of Lucentis in Newly-Diagnosed and Previously Treated Subjects with Age-Related Macular Degeneration.

**RhuFab V2 (ranibizumab) – Principal Investigator**

Genentech, Inc.  
2003 - 2005  
Protocol FVF2587g

A Phase III Multicenter, Randomized, Double-Masked, Active Treatment-Controlled Study of the Efficacy and Safety of RhuFab V2 (ranibizumab) Compared with verteporfin (Visudyne) Photodynamic Therapy in Subjects with Predominantly Classic Subfoveal Neovascular Age-Related Macular Degeneration.

**Verteporfin Photodynamic Therapy – Principal Investigator**

Ciba Vision  
1999 - 2000  
Protocol BPD OCR 005

An Open-Label, Multicenter, Safety Study of the Treatment of Predominantly Classic Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) Using Photodynamic Therapy with Verteporfin for Injection.

### **Flibanserin**

University of Pennsylvania and Boehringer Ingelheim (BI Trial No. 511.11)  
1997 - 1998

An Eight-Week, Double-Blind, Placebo-Controlled Phase II Study of Various Doses of Flibanserin and Paroxetine in Patients with Major Depressive Disorder. Our Role was to Perform Ophthalmic Examinations to Evaluate for Potential Ocular Complications and Side Effects.

### **Pioglitazone**

Takeda America, Inc.  
1996

A Double-Blind Placebo-Controlled, Randomized, Dose-Titration Study to Evaluate the Safety and Efficacy of Pioglitazone, an Oral Hypoglycemic Agent. Our role was to perform retinal examinations and evaluate retinal photographs for evidence of diabetic retinopathy.

### **Adefovir Dipivoxil (bis-POM PMEA)**

NJCRI  
1996 - 1997

A Placebo-Controlled Study of the Safety and Efficacy of Adefovir Dipivoxil (bis-POM PMEA) in Prolonged Survival of HIV-Infected Individuals with a CD4+ Cell Count of  $\leq 100/\text{mm}^3$ . Our role was for ophthalmic evaluation with emphasis on the presence or absence of CMV retinitis.

WILMER EYE INSTITUTE, JOHNS HOPKINS UNIVERSITY. Acted as field supervisor in Liberia for a large scale clinical trial of ivermectin in the treatment of onchocerciasis. 1988.

BRIGHAM AND WOMEN'S HOSPITAL, Boston, MA. Biomedical research on the effects of acidosis on cultured ventricular cells, 1985.

## **BIBLIOGRAPHY**

### **Articles**

Duker, JS, **Margolis TI**: How to treat BRVO. Rev Ophthalmol 1995; 2 (12):50-51.

Avvad FK, Duker JS, Reichel E, **Margolis TI**, Puliafito CA: The digital indocyanine green videoangiography characteristics of well-defined choroidal neovascularization. Ophthalmol 1995; 102:401-405.

**Margolis TI**, Duker JS: Review of "Atlas of Intraocular Tumors". Am J Ophthalmol 1994; 118:688.

**Margolis TI**, Duker JS: Laser treatment of retinal vein occlusion. Ophthalmic Practice 1994; 12 (1):8-12,42.

Borirakchanyavat S, Puliafito CA, Kliman GH, **Margolis TI**, Galler E: Holmium-YAG laser surgery on experimental vitreous membranes. Arch Ophthalmol 1991; 109:1605-1609.

**Margolis TI**, Farnath DA, Destro M, Puliafito CA: Erbium-YAG laser surgery on experimental vitreous membranes. Arch Ophthalmol 1989; 107:424-428.

Marsh JD, **Margolis TI**, Kim D: Mechanism of diminished contractile response to catecholamines during acidosis. Am J Physiol 1988; 254:H20-27.

### Chapters

**Margolis TI**: Contributor to ten sections in Retina and Uveitis chapters. In: Cullum RD and Chang B, ed., The Wills Eye Manual-Office and Emergency Room Diagnosis and Treatment of Eye Disease. Second Edition. J. B. Lippincott Co., Philadelphia, 1994.

### Abstracts

**Margolis TI**, Duker JS, Reichel E, Rutledge BK, Morley MG, Davis JL: Repair of retinal detachments related to cytomegalovirus retinitis in eyes with ganciclovir implants. Invest Ophthalmol Vis Sci 1995; 36(4):S778.

Jivanjee SQ, Duker JS, **Margolis TI**, Reichel E, Puliafito CA, Morley MG: Pneumatic buckle: an alternative technique for the treatment of retinal detachment without subretinal fluid drainage. Invest Ophthalmol Vis Sci 1995; 36(4):S850.

Rutledge BK, Morley MG, Duker JS, **Margolis TI**: Combination antiviral therapy for the progressive outer retinal necrosis syndrome. Invest Ophthalmol Vis Sci 1995; 36(4):S318.

**Margolis TI**, Duker JS, Reichel E, Puliafito CA: Indirect diode laser photocoagulation for threshold and posterior prethreshold retinopathy of prematurity. Invest Ophthalmol Vis Sci 1994; 35(4):1443.

**Margolis TI**, Farnath DA, Puliafito CA: Mid-infrared laser sclerostomy. Invest Ophthalmol Vis Sci 1988; 29 (supp):366.

Farnath, DA, **Margolis TI**, Destro M, Puliafito CA: Erbium-YAG laser surgery on experimental vitreous membranes in rabbits. Invest Ophthalmol Vis Sci 1988; 29 (supp):292.

Borirak S, **Margolis TI**, Kliman GH, Puliafito CA: Holmium-YAG laser surgery on experimental vitreous membranes in rabbits. Invest Ophthalmol Vis Sci 1989; 30 (supp):372.

